Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Post-ibrutinib relapse outcomes for patients with marginal zone lymphoma

Geoffrey Shouse, DO, PhD, City of Hope Comprehensive Cancer Center, Duarte, CA, briefly discusses a retrospective study which investigated the outcomes of patients with marginal zone lymphoma (MZL) who progressed after treatment with ibrutinib, and highlights the need for better therapeutic options for these patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Kite Pharma: Speakers Bureau; Beigene Inc USA: Honoraria.